AI has ‘untapped potential’ for entrepreneurs

AI applications in healthcare are just ramping up, allowing for an influx of entrepreneurs, according to a new report from Entrepreneur.

“This technology stands on the cusp, ready to improve nearly every industry; and it offers a myriad of opportunities for entrepreneurs able to imagine and execute new applications for the future,” wrote guest writer Brian Hughes, CEO of Integrity Marketing & Consulting.

The healthcare-focused AI market is expected to grow into a $36.1 billion industry, which translates to 50 percent growth through 2025. Financing for AI-based technologies is also increasing, as AI is already used in a variety of clinical settings—and frequently in imaging. But Hughes noted there is “untapped potential” which could bring “a wealth of opportunities” specific to entrepreneurs. 

“From research to diagnosis and treatment, the AI applications in healthcare have barely scratched the surface, leaving a wide field for entrepreneurs to enter,” Hughes said.

To read the story, click the link below.

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.